Cyrenaic Pharmaceuticals Inc., a private drug development company focused on the treatment of CNS disorders, announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of more
To use all functions of this page, please activate cookies in your browser.
